- Home
- LSF vs EPIX Comparison
LSF vs EPIX Comparison
Compare LSF & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- EPIX
- Stock Information
- Founded
- LSF 2015
- EPIX 2009
- Country
- LSF United States
- EPIX Canada
- Employees
- LSF N/A
- EPIX N/A
- Industry
- LSF Packaged Foods
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- EPIX Health Care
- Exchange
- LSF Nasdaq
- EPIX Nasdaq
- Market Cap
- LSF 73.2M
- EPIX 71.5M
- IPO Year
- LSF 2020
- EPIX N/A
- Fundamental
- Price
- LSF $6.54
- EPIX $1.72
- Analyst Decision
- LSF Strong Buy
- EPIX Hold
- Analyst Count
- LSF 1
- EPIX 3
- Target Price
- LSF $12.00
- EPIX $2.00
- AVG Volume (30 Days)
- LSF 55.3K
- EPIX 116.5K
- Earning Date
- LSF 05-07-2025
- EPIX 05-08-2025
- Dividend Yield
- LSF N/A
- EPIX N/A
- EPS Growth
- LSF N/A
- EPIX N/A
- EPS
- LSF N/A
- EPIX N/A
- Revenue
- LSF $45,040,358.00
- EPIX N/A
- Revenue This Year
- LSF $23.40
- EPIX N/A
- Revenue Next Year
- LSF $20.11
- EPIX N/A
- P/E Ratio
- LSF N/A
- EPIX N/A
- Revenue Growth
- LSF 25.04
- EPIX N/A
- 52 Week Low
- LSF $2.77
- EPIX $1.40
- 52 Week High
- LSF $10.90
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- LSF 49.33
- EPIX 56.25
- Support Level
- LSF $6.20
- EPIX $1.60
- Resistance Level
- LSF $6.67
- EPIX $1.70
- Average True Range (ATR)
- LSF 0.40
- EPIX 0.05
- MACD
- LSF -0.13
- EPIX 0.00
- Stochastic Oscillator
- LSF 21.83
- EPIX 100.00
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.